MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is broadening the capabilities of its AI-driven voice analytics platform to include fatigue detection, alongside its existing drug and alcohol impairment screening. The company announced May 11 that it has developed a fatigue recognition system using speech analytics and proprietary artificial intelligence models, according to a news release (https://ibn.fm/4KNzG). This expansion positions MindBio to address a critical safety concern in high-risk workplace environments where fatigue can be as dangerous as intoxication.
The fatigue detection capability will be integrated into MindBio’s planned Edge AI Intoxication Detection Kiosks, which are designed to identify signs of impairment through voice analysis. The company has filed a patent application covering the detection of neurologically active substances and fatigue via voice analysis. Management stated that commercial testing of the kiosk hardware and software remains on track for late Q2 2026. The technology is being positioned as a non-invasive alternative to traditional breath, saliva, blood, and laboratory-based testing systems.
Initial target sectors for deployment include mining, aviation, transportation, and construction—industries where operator alertness is critical for safety. Fatigue is a known contributor to workplace accidents, and the ability to detect it non-invasively could help employers mitigate risks. MindBio’s approach leverages edge AI, processing voice data locally on the kiosk without sending sensitive biometric information to the cloud, which may address privacy concerns.
The company’s expansion into fatigue detection follows its core focus on intoxication screening. By adding fatigue recognition, MindBio aims to offer a more comprehensive safety solution. The patent application signals the company’s intent to protect its intellectual property in the growing field of voice-based health monitoring. Investors can find the latest news and updates regarding MBQIF in the company’s newsroom at https://ibn.fm/MBQIF.
MindBio’s technology represents a shift toward non-invasive, real-time impairment detection. If successful, it could reduce reliance on cumbersome and sometimes inaccurate traditional testing methods. The commercial testing timeline in late Q2 2026 will be a key milestone for the company as it seeks to validate its platform in real-world industrial settings. The integration of fatigue detection could also open up additional markets beyond safety, such as in transportation logistics and long-haul driving.
